BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO.B - US0905721082 - Common Stock
310.7 USD
-3.7 (-1.18%)
Taking everything into account, BIO.B scores 4 out of 10 in our fundamental rating. BIO.B was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO.B is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO.B was profitable.
BIO.B had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIO.B has a Return On Assets (-6.97%) which is in line with its industry peers.
BIO.B has a Return On Equity (-10.03%) which is in line with its industry peers.
BIO.B has a better Return On Invested Capital (2.26%) than 62.07% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO.B's Operating Margin of 10.27% is fine compared to the rest of the industry. BIO.B outperforms 70.69% of its industry peers.
In the last couple of years the Operating Margin of BIO.B has remained more or less at the same level.
Looking at the Gross Margin, with a value of 52.42%, BIO.B is in the better half of the industry, outperforming 63.79% of the companies in the same industry.
BIO.B's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BIO.B has been reduced compared to 1 year ago.
BIO.B has less shares outstanding than it did 5 years ago.
BIO.B has a worse debt/assets ratio than last year.
2.2 Solvency
BIO.B has an Altman-Z score of 3.42. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BIO.B (3.42) is better than 62.07% of its industry peers.
BIO.B has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO.B would need 3.57 years to pay back of all of its debts.
BIO.B has a Debt to FCF ratio of 3.57. This is in the better half of the industry: BIO.B outperforms 77.59% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that BIO.B is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.18, BIO.B is in line with its industry, outperforming 56.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.42 |
ROIC/WACC0.23
WACC9.97%
2.3 Liquidity
BIO.B has a Current Ratio of 5.44. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
BIO.B has a Current ratio of 5.44. This is amongst the best in the industry. BIO.B outperforms 86.21% of its industry peers.
A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.94, BIO.B is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased by -1.90% in the last year.
BIO.B shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.84% yearly.
The Revenue has decreased by -0.88% in the past year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
Based on estimates for the next years, BIO.B will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 30.14, which means the current valuation is very expensive for BIO.B.
70.69% of the companies in the same industry are more expensive than BIO.B, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BIO.B to the average of the S&P500 Index (27.19), we can say BIO.B is valued inline with the index average.
BIO.B is valuated quite expensively with a Price/Forward Earnings ratio of 29.92.
Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than 68.97% of the companies in the same industry.
BIO.B's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.92 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued a bit cheaper than 79.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.89 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.85
EPS Next 2Y0.36%
EPS Next 3Y3.89%
5. Dividend
5.1 Amount
BIO.B does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (11/17/2025, 8:04:00 PM)
310.7
-3.7 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.44%
Inst Owner Change0%
Ins Owners8.18%
Ins Owner ChangeN/A
Market Cap8.38B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target363.55 (17.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)-1.58%
PT rev (3m)-1.58%
EPS NQ rev (1m)-2.73%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)-0.35%
EPS NY rev (3m)18.63%
Revenue NQ rev (1m)-1.14%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)2.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.14 | ||
| Fwd PE | 29.92 | ||
| P/S | 3.28 | ||
| P/FCF | 24.89 | ||
| P/OCF | 17.05 | ||
| P/B | 1.24 | ||
| P/tB | 1.45 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.32%
EPS(NY)10.38
Fwd EY3.34%
FCF(TTM)12.48
FCFY4.02%
OCF(TTM)18.22
OCFY5.87%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.85
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.42 |
F-Score5
WACC9.97%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.94%
EPS Next 2Y0.36%
EPS Next 3Y3.89%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.31%
Revenue Next 2Y1.3%
Revenue Next 3Y2.08%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y15.44%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 7 / 10.